정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
65 | Not yet recruiting | Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19 | Corona Virus Infection | Biological: UCMSCs Other: Placebo |
Phase 1 | Joshua M Hare | OTHER | 21 | All | 18 Years | University of Miami, Miami, Florida, United States |
64 | Recruiting | Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia | Pneumonia, Ventilator-Associated | Biological: UC-MSCs | Phase 2 | ZhiYong Peng, Tuohua Biological Technology Co. Ltd | OTHER | 16 | All | 18 Years ~ 80 Years | Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China |
63 | Enrolling by invitation | Umifenovir in Hospitalized COVID-19 Patients | COVID-19 | Drug: Umifenovir Drug: Interferon-β 1a Drug: Lopinavir / Ritonavir Drug: Single Dose of Hydroxychloroquine Drug: Standards of Care |
Phase 4 | Shahid Beheshti University of Medical Sciences | OTHER | 40 | All | 18 Years | Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of |
62 | Recruiting | Universal Anti-Viral Vaccine for Healthy Elderly Adults | ARDS, Human | Drug: AlloStim | Phase 2 | Immunovative Therapies, Ltd., Mirror Biologics, Inc. | INDUSTRY | 40 | All | 65 Years | Florida Medical Clinic, LLC, Zephyrhills, Florida, United States |
61 | Active, not recruiting | University of Utah COVID-19 Hydrochloroquine Trial | Infectious Disease | Drug: Hydroxychloroquine Drug: Placebo oral tablet |
Phase 2 | University of Utah | OTHER | 368 | All | 18 Years | University of Utah, Salt Lake City, Utah, United States |
60 | Recruiting | Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease | Covid19 | Drug: Part A: Upamostat 200 mg Drug: Part A: Upamostat 400 mg Drug: Part A and B: Placebo Drug: Part B: Upamostat 200 or 400 mg |
Phase 3 | RedHill Biopharma Limited | INDUSTRY | 310 | All | 18 Years | Beautiful Minds Clinical Research, Cutler Bay, Florida, United States Research in Miami Inc., Hialeah, Florida, United States South Florida Research Phase I-IV, Inc., Miami Springs, Florida, United States Angels Clinical Research Institute, Miami, Florida, United States Great Lakes Research Group, Bay City, Michigan, United States Henry Ford Hospital, emergency department, Detroit, Michigan, United States Prime Global Research, Bronx, New York, United States Montefiore Medical Center, Bronx, New York, United States On-Site Clinical Solutions, Charlotte, North Carolina, United States On-Site Clinical Solutions, Charlotte, North Carolina, United States University Hospitals Cleveland, Cleveland, Ohio, United States Southwest Family Medicine Research, Dallas, Texas, United States Langeberg Medical Centre - Clinical Trials, Kraaifontein, Cape Town, South Africa Roodepoort Medicross Clinical Trial Research Centre, Roodepoort, Gauteng, South Africa FCRN Clinical Trial Centre, Vereeniging, Gauteng, South Africa PJ Sebastian, KwaZulu, Natal, South Africa Global Clinical Trials PTY (LTD), Arcadia, Pretoria, South Africa WorthWhile Clinical Trials, Benoni, South Africa |
59 | Recruiting | UPMC OPTIMISE-C19 Trial, a COVID-19 Study | Covid19 | Biological: Lilly Bamlanivimab Biological: Regeneron Casirivimab + Imdevimab Biological: Lilly Bamlanivimab + Etesevimab Biological: Sotrovimab |
Phase 3 | David T Huang, University of Pittsburgh Medical Center, Berry Consultants | OTHER | 5000 | All | 12 Years ~ 120 Years | UPMC, Pittsburgh, Pennsylvania, United States |